Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Gains from Sales and Divestitures (2022 - 2025)

Lyra Therapeutics has reported Gains from Sales and Divestitures over the past 4 years, most recently at $41250.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $41250.0 for Q4 2025, down 52.35% from a year ago — trailing twelve months through Dec 2025 was $41250.0 (down 52.35% YoY), and the annual figure for FY2025 was $41250.0, down 52.35%.
  • Gains from Sales and Divestitures for Q4 2025 was $41250.0 at Lyra Therapeutics, up from $34182.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for LYRA hit a ceiling of $365121.0 in Q1 2025 and a floor of $1302.0 in Q2 2022.
  • Median Gains from Sales and Divestitures over the past 4 years was $21486.5 (2024), compared with a mean of $54122.9.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 1722.65% in 2024 and later crashed 52.35% in 2025.
  • Lyra Therapeutics' Gains from Sales and Divestitures stood at $1953.0 in 2022, then surged by 260.52% to $7041.0 in 2023, then surged by 1129.57% to $86574.0 in 2024, then crashed by 52.35% to $41250.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $41250.0 (Q4 2025), $34182.0 (Q3 2025), and $15104.0 (Q2 2025) per Business Quant data.